NCT01999920

Vilazodone for Separation Anxiety Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: New York State Psychiatric Institute · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine whether Vilazodone (Viibryd), an SSRI and 5HT1a receptor agonist, is effective in treating Adult Separation Anxiety Disorder over a 12-week treatment course.

Detailed description

In this randomized clinical trial, 40 adults with a principal diagnosis of Adult Separation Anxiety Disorder (ASAD) and no major depression or substance abuse disorders will be randomized to 12 weeks of treatment with vilazodone (flexibly dosed) or matched pill placebo. Outcome will be assessed in respect to symptomatic improvement, quality of life, adverse events and safety.

Conditions

• Separation Anxiety Disorder

Interventions

Type	Name	Description
DRUG	Vilazodone	10mg to 40mg per day for 12 weeks
DRUG	Placebo	One to two pills per day for 12 weeks

Timeline

• Start date: 2013-12-01
• Primary completion: 2017-03-01
• Completion: 2017-12-30
• First posted: 2013-12-03
• Last updated: 2018-03-07
• Results posted: 2017-10-31

Locations

1 site across 1 country: United States